Loading institutional data...
Loading institutional data...
Held by 636 of 5,944 reporting institutions (98th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$968M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -100%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $510M covers the $0 due within a year 510445000.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~15.5% on $541M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 14-yr range · 76th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 24.6 | 17.7 | 24.3 | 23.4 | 22.5 | 21.5 | 23.6 | 20.3 |
| Gross Profit | 75.4 | 82.3 | — | — | — | — | — | — |
| R&D | 1477.2 | 96.5 | 110.2 | 144.7 | 162.0 | 187.1 | 164.5 | 127.2 |
| SG&A | 1710.4 | 154.5 | 123.8 | 124.3 | 108.3 | 112.9 | 126.8 | 115.6 |
| Operating Income | -3124.9 | -172.4 | -161.3 | -199.0 | -186.4 | -232.5 | -241.5 | -205.6 |
| Income Tax | 2.0 | 0.6 | 0.9 | -0.9 | 0.6 | 0.8 | 1.0 | 0.8 |
| Net Income | -3297.2 | -186.4 | -178.9 | -230.6 | -196.3 | -245.6 | -251.2 | -210.5 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on INSM: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $606.4M 100.0% | $363.7M 100.0% | $305.2M 100.0% | $245.4M 100.0% | $188.5M 100.0% | $164.4M 100.0% | $136.5M 100.0% | $9.8M 100.0% | $0 | $0 |
| Cost of Revenue | $122.9M 20.3% | $85.7M 23.6% | $65.6M 21.5% | $55.1M 22.5% | $44.2M 23.4% | $39.9M 24.3% | $24.2M 17.7% | $2.4M 24.6% | $0 | $0 |
| Gross Profit | — | — | — | — | — | — | $112.3M 82.3% | $7.4M 75.4% | $0 | — |
| Research & Development | $771.1M 127.2% | $598.4M 164.5% | $571.0M 187.1% | $397.5M 162.0% | $272.7M 144.7% | $181.2M 110.2% | $131.7M 96.5% | $145.3M 1477.2% | $109.7M | $122.7M |
| Selling, General & Admin | $701.2M 115.6% | $461.1M 126.8% | $344.5M 112.9% | $265.8M 108.3% | $234.3M 124.3% | $203.6M 123.8% | $210.8M 154.5% | $168.2M 1710.4% | $79.2M | $50.7M |
| Total Operating Expenses | $1.85B 305.6% | $1.24B 341.5% | $1.01B 332.5% | $702.7M 286.4% | $563.6M 299.0% | $429.6M 261.3% | $371.7M 272.4% | $317.2M 3224.9% | $188.9M | $173.4M |
| Operating Income | -$1.25B -205.6% | -$878.3M -241.5% | -$709.6M -232.5% | -$457.3M -186.4% | -$375.1M -199.0% | -$265.2M -161.3% | -$235.2M -172.4% | -$307.3M -3124.9% | -$188.9M | -$173.4M |
| Interest Expense | $83.8M 13.8% | $84.9M 23.3% | $81.7M 26.8% | $26.4M 10.8% | $40.5M 21.5% | $29.6M 18.0% | $27.7M 20.3% | $25.5M 259.0% | $5.9M | $3.5M |
| Other Income (Expense), net | -$1.8M -0.3% | $29K 0.0% | $1.9M 0.6% | -$5.9M -2.4% | -$3.3M -1.8% | $405K 0.2% | -$531K -0.4% | $602K 6.1% | $300K | $119K |
| Pretax Income | -$1.27B -209.7% | -$910.1M -250.2% | -$747.0M -244.8% | -$480.2M -195.7% | -$436.4M -231.6% | -$292.7M -178.0% | -$253.6M -185.8% | -$324.1M -3295.1% | -$192.9M | -$176.2M |
| Income Tax Expense | $5.0M 0.8% | $3.7M 1.0% | $2.6M 0.8% | $1.4M 0.6% | -$1.8M -0.9% | $1.4M 0.9% | $777K 0.6% | $201K 2.0% | -$272K | $98K |
| Net Income | -$1.28B -210.5% | -$913.8M -251.2% | -$749.6M -245.6% | -$481.5M -196.3% | -$434.7M -230.6% | -$294.1M -178.9% | -$254.3M -186.4% | -$324.3M -3297.2% | -$192.6M | -$176.3M |
| Per Share | ||||||||||
| EPS (Basic) | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | — | — | — |
| EPS (Diluted) | $-6.42 | $-5.57 | $-5.34 | $-3.91 | $-3.88 | $-3.01 | $-3.01 | — | — | — |
| Weighted Avg Shares (Basic) | 199.0M | 164.0M | 140.4M | 123.0M | 112.1M | 97.6M | 84.6M | 76.9M | 66.6M | 61.9M |
| Weighted Avg Shares (Diluted) | 199.0M | 164.0M | 140.4M | 123.0M | 112.1M | 97.6M | 84.6M | 76.9M | 66.6M | 61.9M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| INSM | $26.3B | — | — | 43.3× | 66.7% | 79.7% | -211% | -173% | -99.8% | -0.4× | 636 |
Peers = companies sharing INSM's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.